San Donato Hospital
| Italia | Turchia | Austria | |
| Trapianto di midollo osseo allogenico da donatore non correlato | da $150,000 | da $80,000 | da $180,000 |
| Trapianto di midollo osseo allogenico da donatore consanguineo | da $120,000 | da $65,000 | da $150,000 |
| Trapianto di midollo osseo | da $95,000 | da $36,000 | da $140,000 |
| Trapianto autologo di midollo osseo | da $90,000 | da $31,500 | da $50,000 |
| Radioterapia per il cancro colorettale | da $7,000 | da $7,000 | da $12,000 |
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Linfoma di Burkitt. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Linfoma di Burkitt e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Linfoma di Burkitt.
Il Professor Fabio Ciceri guida rivoluzionari studi clinici in terapia cellulare e genica per i tumori ematologici presso l'Ospedale San Raffaele.
Il medico è il Vice Direttore del Dipartimento di Ematologia Oncologica e Direttore dell'Unità di Linfoma presso l'Istituto Scientifico San Raffaele, con un focus sul trattamento del linfoma. <\/p>
È il fondatore della Fondazione Italiana Linfoma, dedicata all'avanzamento degli studi clinici nella gestione del linfoma. <\/p>
Il suo background accademico include una laurea in medicina generale e chirurgia presso l'Università di Buenos Aires e l'Università di Parma, e una specializzazione in oncologia medica presso l'Università di Milano. <\/p>
Il medico ha scritto oltre 300 articoli sul trattamento del linfoma ed è membro di diverse società prestigiose di ematologia e oncologia.<\/p>
Italian oncology centers treat Burkitt lymphoma with intensive multiagent immunochemotherapy. This standard first-line therapy combines rituximab with aggressive chemo-blocks to target fast-growing cells. Specialized protocols include central nervous system prophylaxis and urgent tumor lysis syndrome prevention to ensure patient safety.
Bookimed Expert Insight: Italian research hospitals like San Raffaele prioritize integration between research and clinical care. Their IRCCS accreditation means patients often access established international protocols under the guidance of hematology leaders. Dr. Fabio Ciceri at San Raffaele leads a specialized unit where bone marrow transplantation is integrated into care if initial therapy response requires escalation.
Patient Consensus: Patients emphasize that treatment must start immediately after diagnosis because of rapid tumor growth. They note that initial cycles usually require staying in the hospital for close monitoring and fluids.
Central nervous system (CNS) preventive measures are standard for Burkitt lymphoma in Italy. Italian oncology protocols utilize proactive CNS prophylaxis due to the high risk of relapse. These measures typically include intrathecal chemotherapy administered via lumbar puncture during the primary treatment cycle.
Bookimed Expert Insight: While prophylaxis is standard, our data shows patients often choose IRCCS-accredited research hospitals like San Raffaele in Milan for Burkitt lymphoma. These facilities, led by experts like Professor Fabio Ciceri, integrate gene therapy research with hematology. Choosing a research hospital ensures access to precise cytogenetic analysis before finalizing your CNS prevention plan.
Patient Consensus: Patients note that CNS prevention isn't a one-time step. It usually requires several lumbar punctures. Many emphasize confirming whether a lumbar puncture or an Ommaya reservoir will be used for delivery.
Italy treats resistant Burkitt lymphoma with intensive salvage chemotherapy followed by hematopoietic stem cell transplantation. Specialized IRCCS research hospitals provide access to CAR T-cell therapy and clinical trials. Italian oncohematologists use aggressive protocols like R-ICE and R-CYVE to induce second remission in patients.
Bookimed Expert Insight: Italian IRCCS centers like San Raffaele combine research with clinical care. Dr. Fabio Ciceri leads the Bone Marrow Transplantation Unit there. These institutions perform over 8,400 operations yearly. They specialize in rare immune diseases and gene therapy trials. This infrastructure is vital for managing high-grade lymphomas like Burkitt.
Patient Consensus: Patients emphasize the need for rapid pathology reviews at major university hospitals. Traveling to a well-equipped tertiary center is better than choosing a local hospital.
Italian studies report Burkitt lymphoma cure rates ranging from 67% to 94%. Outcomes depend on age and risk profiles. Low-risk patients demonstrate 100% cure rates in multicenter trials. Intensive short-term chemotherapy programs achieve 92% survival in children and 78% overall 5-year survival in adults.
Bookimed Expert Insight: Italian research leadership is driven by specialized groups like the Northern Italy Leukemia Group. Experts like Dr. Fabio Ciceri at San Raffaele in Milan are active members. This ensures patients access protocols that improved response rates from 80% to 94% through intensive salvage regimens.
Patient Consensus: Patients emphasize that treatment success depends on starting aggressive chemotherapy quickly after diagnosis. They note that managing therapy toxicity is the most challenging part of the recovery process.
Elderly patients safely receive aggressive Burkitt's lymphoma regimens in Italian hospitals through rigorous risk stratification. Fitness assessments prioritize biological health over chronological age. Success depends on specialized screening tools. Multidisciplinary teams at IRCCS-accredited centers manage treatments to ensure safety for patients over 65.
Bookimed Expert Insight: Italian IRCCS-accredited hospitals like San Raffaele combine research with clinical care to manage rare hematological cancers. Data shows that elderly patients succeed most when treated by specialists like Professor Fabio Ciceri. His expertise in bone marrow transplantation and cell therapy at a center performing 52,000 yearly operations provides a critical safety net for high-risk protocols.
Patient Consensus: Patients emphasize that a hospital's ability to manage tumor lysis syndrome and rapid infections is more important than age. They suggest seeking larger academic units where monitoring is frequent and supportive care is available 24/7.
Patients choose Italy for Burkitt's lymphoma care due to high success rates and specialized research protocols. Centers like San Raffaele utilize the CARMEN protocol for complex cases. These facilities provide rapid intervention. They offer advanced cellular therapies under strict European Union medical regulations.
Bookimed Expert Insight: Milan centers offer a unique advantage because they serve over 300,000 patients annually. This high volume across San Raffaele and San Donato ensures specialists see rare cases more frequently. Dr. Fabio Ciceri's 20+ years of expertise is coupled with active clinical trials. This combination provides drug access that many general hospitals cannot match.
Patient Consensus: Patients value how Italian university hospitals provide a fast second opinion on rare lymphoma pathology. They note it's vital to have a local oncologist ready to coordinate follow-up care after returning home.